Clearside Overview Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. Quarterly Summary Show all Latest Quarterly Results Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update Clearside Biomedical Q1 2022 Financial Results and Corporate Update Call Form 10-Q View All News Releases Jun 14 2022 Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer Jun 8 2022 Clearside Biomedical to Participate in the JMP Securities Life Sciences Conference May 11 2022 Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update View All Events JMP Securities Life Sciences Conference Jun 15, 2022 at 9:30 AM EDT Clearside Biomedical Q1 2022 Financial Results and Corporate Update Call May 11, 2022 at 4:30 PM EDT Needham Virtual Healthcare Conference Apr 13, 2022 at 3:45 PM EDT View All Stock Quote Change Volume 52 Week High 52 Week Low Jun 29, 2022 3:53 PM EDT Data Provided by Refinitiv. Minimum 15 minutes delayed.